mencevax ac pws inj 2500mcg/vial powder for solution
glaxosmithkline inc - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; sodium chloride - powder for solution - 2.5mg; 2.5mg; 25ml - meningococcal polysaccharide antigen group a 2.5mg; meningococcal polysaccharide antigen group c 2.5mg; sodium chloride 25ml - vaccines
menomune-a/c/y/w-135 powder for solution
aventis pasteur limited - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group y; meningococcal polysaccharide antigen group w-135 - powder for solution - 2.5mg; 2.5mg; 2.5mg; 2.5mg - meningococcal polysaccharide antigen group a 2.5mg; meningococcal polysaccharide antigen group c 2.5mg; meningococcal polysaccharide antigen group y 2.5mg; meningococcal polysaccharide antigen group w-135 2.5mg - vaccines
neisvac-c suspension
pfizer canada ulc - meningococcal polysaccharide vaccine grp c; tetanus toxoid - suspension - 10mcg; 20mcg - meningococcal polysaccharide vaccine grp c 10mcg; tetanus toxoid 20mcg - vaccines
menitorix combined hib-menc conjugate vaccine powder for injection vial plus diluent syringe
glaxosmithkline australia pty ltd - haemophilus influenza type b polyribose ribitol phosphate,meningococcal polysaccharide group c,tetanus toxoid -
neisvac-c vaccine meningococcal group c polysaccharide conjugate vaccine suspension for injection syringe
pfizer australia pty ltd - tetanus toxoid, quantity: 20 microgram/ml; meningococcal polysaccharide group c, quantity: 20 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; water for injections; aluminium hydroxide hydrate - neisvac-c vaccine is indicated for active immunisation of children from 8 weeks of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis serogroup c.
mencevax acwy vaccine
glaxosmithkline australia pty ltd - meningococcal polysaccharide - group w135; meningococcal polysaccharide - group a; meningococcal polysaccharide - group y; meningococcal polysaccharide - group c -
menomune
sanofi-aventis australia pty ltd - meningococcal polysaccharide - group a; meningococcal polysaccharide - group w135; meningococcal polysaccharide - group y; meningococcal polysaccharide - group c -
menveo meningococcal (groups a, c, w-135 and y) oligosaccharide crm197 conjugate vaccine
glaxosmithkline australia pty ltd - meningococcal oligosaccharide group y, quantity: 5 microgram; meningococcal oligosaccharide group c, quantity: 5 microgram; diphtheria crm197 protein, quantity: 16 microgram; meningococcal oligosaccharide group w135, quantity: 5 microgram - injection, solution - excipient ingredients: sodium chloride; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate - menveo is indicated for active immunisation of infants and children (from 2 months of age), adolescents and adults to prevent invasive disease caused by neisseria meningitidis serogroups a, c, w-135 and y. the use of this vaccine should be in accordance with official recommendations.
menveo
gsk vaccines s.r.l. - meningococcal group a, c, w-135 and y conjugate vaccine - immunization, meningitis, meningococcal - bacterial vaccines - prefilled syringe menveo is indicated for active immunisation of adolescents (from 11 years of age) and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations. vials menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.,
mencevax acwy vaccine
pfizer new zealand limited - neisseria meningitidis group a polysaccharide 50ug; ; neisseria meningitidis group c polysaccharide 50ug; ; neisseria meningitidis group w135 polysaccharide 50ug; ; neisseria meningitidis group y polysaccharide 50ug; - suspension for injection - 50µg/0.5ml - active: neisseria meningitidis group a polysaccharide 50ug neisseria meningitidis group c polysaccharide 50ug neisseria meningitidis group w135 polysaccharide 50ug neisseria meningitidis group y polysaccharide 50ug excipient: sucrose trometamol sodium chloride water for injection - mencevax acwy is indicated for active immunisation of adults and children over two years against meningococcal meningitis caused by group a, group c, group w-135 and group y meningococci. the vaccine may also be used for: · subjects who are close contacts of patients with disease caused by meningococci of groups a, c, w-135 and y. · travellers to countries where the disease is epidemic or highly endemic. · controlling epidemics of infection caused by group a, c, w-135, y meningococci in confined communities. mencevax acwy is not recommended for use in infants and children under two years of age, as antigenicity of the vaccine is low in this age group and antibodies persist for shorter duration.